Download Files:
LY2886721
$90 – $858
Products Details
Product Description
– LY2886721 is a potent, selective and orally active beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor with an IC50 of 20.3 nM for recombinant human BACE1. LY2886721 is selectivity against cathepsin D, pepsin, and renin, but lacking selectivity against BACE2 (IC50 of 10.2 nM). LY2886721 can across blood-brain barrier and has the potential for Alzheimer’s disease treatment[1].
Web ID
– HY-13240
Storage Temperature
– -20°C, 3 years (Powder)
Shipping
– Blue Ice
Applications
– Neuroscience-Neurodegeneration
Molecular Formula
– C18H16F2N4O2S
References
– [1]May PC1, et al. The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans. J Neurosci. 2015 Jan 21;35(3):1199-210.
CAS Number
– 1262036-50-9
Molecular Weight
– 390.41
Compound Purity
– 99.74
SMILES
– FC1=CN=C(C=C1)C(NC2=CC=C(C([C@@]34[C@]([H])(CSC(N)=N4)COC3)=C2)F)=O
Clinical Information
– Phase 2
Research Area
– Neurological Disease
Solubility
– DMSO : ≥ 16.67 mg/mL
Target
– Beta-secretase
Isoform
– BACE1
Pathway
– Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
